Although patients with castration-resistant prostate cancer frequently have metastases to the bone, they have a relatively favorable prognosis.
Therefore, it is important to keep or improve the level of patient's quality of life. The use of strontium-89 for the management of the pain from bone metastasis was approved in 2007 in Japan. A new bone-targeting radiopharmaceuticals using radium-223 is also promising, because a randomized trial showed an overall survival advantage of radium-223 in prostate patients with bone metastases. In this review, we summarize the role of targeted radionuclide therapy for castration-resistant prostate cancer, focusing on strontium-89 and radium-223.
Written by:
Nakamura K, Ohga S, Sasaki T, Baba S, Honda H. Are you the author?
Reference: Nihon Rinsho. 2014 Dec;72(12):2181-5.
PubMed Abstract
PMID: 25518355
Article in Japanese.